{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:47:25Z","timestamp":1791488845892,"version":"4.3.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Not applicable","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12910-017-0201-1","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T07:58:34Z","timestamp":1498463914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic"],"prefix":"10.1186","volume":"18","author":[{"given":"Emilie","family":"Alirol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette C.","family":"Kuesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Magdalena","family":"Guraiib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2nia","family":"de la Fuente-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba F.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"201_CR1","unstructured":"World Health Organization: Statement on the 9th meeting of the IHR Emergency Committee regarding the Ebola outbreak in West Africa. http:\/\/who.int\/mediacentre\/news\/statements\/2016\/end-of-ebola-pheic\/en\/ (2016). Accessed 08 Aug 2016."},{"key":"201_CR2","unstructured":"World Health Organization: Meeting summary of the WHO consultation on potential Ebola therapies and vaccines. http:\/\/apps.who.int\/iris\/handle\/10665\/136103 (2014). Accessed 14 Aug 2016."},{"key":"201_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1471-2334-11-357","volume":"11","author":"M Borchert","year":"2011","unstructured":"Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis. 2011;11:357.","journal-title":"BMC Infect Dis"},{"key":"201_CR4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/004947550203200107","volume":"32","author":"M Bitekyerezo","year":"2002","unstructured":"Bitekyerezo M, Kyobutungi C, Kizza R, Mugeni J, Munyarugero E, Tirwomwe F, et al. The outbreak and control of Ebola viral haemorrhagic fever in a Ugandan medical school. Trop Dr. 2002;32:10\u20135.","journal-title":"Trop Dr"},{"issue":"Suppl 1","key":"201_CR5","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1086\/514306","volume":"179","author":"AS Khan","year":"1999","unstructured":"Khan AS, Tshioko FK, Heymann DL, Le GB, Nabeth P, Kerstiens B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179(Suppl 1):S76\u201386.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"201_CR6","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1086\/514302","volume":"179","author":"JJ Muyembe-Tamfum","year":"1999","unstructured":"Muyembe-Tamfum JJ, Kipasa M, Kiyungu C, Colebunders R. Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J Infect Dis. 1999;179(Suppl 1):S259\u201362.","journal-title":"J Infect Dis"},{"key":"201_CR7","unstructured":"Outbreak of Ebola hemorrhagic fever Uganda, August 2000\u2013January 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 73-77."},{"issue":"Suppl 1","key":"201_CR8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/514308","volume":"179","author":"MA Bwaka","year":"1999","unstructured":"Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De RA, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179(Suppl 1):S1\u20137.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"201_CR9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","volume":"179","author":"K Mupapa","year":"1999","unstructured":"Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International scientific and technical committee. J Infect Dis. 1999;179(Suppl 1):S18\u201323.","journal-title":"J Infect Dis"},{"key":"201_CR10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJMc1415318","volume":"372","author":"J Agua-Agum","year":"2015","unstructured":"Agua-Agum J, Ariyarajah A, Blake IM, Cori A, Donnelly CA, Dorigatti I, et al. Ebola virus disease among children in West Africa. N Engl J Med. 2015;372:1274\u20137.","journal-title":"N Engl J Med"},{"key":"201_CR11","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMoa1411100","volume":"371","author":"B Aylward","year":"2014","unstructured":"Aylward B, Barboza P, Bawo L, Bertherat E, Bilivogui P, Blake I, et al. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481\u201395.","journal-title":"N Engl J Med"},{"key":"201_CR12","doi-asserted-by":"crossref","first-page":"e0140810","DOI":"10.1371\/journal.pone.0140810","volume":"10","author":"YH Hsieh","year":"2015","unstructured":"Hsieh YH. Temporal course of 2014 Ebola virus disease (EVD) outbreak in West Africa elucidated through morbidity and mortality data: a tale of three countries. PLoS One. 2015;10:e0140810.","journal-title":"PLoS One"},{"key":"201_CR13","unstructured":"World Health Organization: Potential Ebola therapies and vaccines: interim guidance. http:\/\/apps.who.int\/iris\/handle\/10665\/137590 (2014). Accessed 14 Aug 2016."},{"key":"201_CR14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2008.01.152","volume":"78","author":"DG Bausch","year":"2008","unstructured":"Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antivir Res. 2008;78:150\u201361.","journal-title":"Antivir Res"},{"key":"201_CR15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786\u201390.","journal-title":"Nat Med"},{"key":"201_CR16","doi-asserted-by":"crossref","first-page":"e5547","DOI":"10.1371\/journal.pone.0005547","volume":"4","author":"X Qiu","year":"2009","unstructured":"Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009;4:e5547.","journal-title":"PLoS One"},{"key":"201_CR17","doi-asserted-by":"crossref","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","volume":"4","author":"TW Geisbert","year":"2008","unstructured":"Geisbert TW, Daddario-DiCaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.","journal-title":"PLoS Pathog"},{"key":"201_CR18","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","volume":"83","author":"TW Geisbert","year":"2009","unstructured":"Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296\u2013304.","journal-title":"J Virol"},{"key":"201_CR19","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","volume":"85","author":"TW Geisbert","year":"2011","unstructured":"Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222\u201333.","journal-title":"J Virol"},{"key":"201_CR20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","volume":"346","author":"GP Kobinger","year":"2006","unstructured":"Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394\u2013401.","journal-title":"Virology"},{"key":"201_CR21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","volume":"13","author":"JE Martin","year":"2006","unstructured":"Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267\u201377.","journal-title":"Clin Vaccine Immunol"},{"key":"201_CR22","unstructured":"WHO Advisory Panel: Ethical considerations for use of unregistered interventions for Ebola virus disease. Report of an advisory panel to WHO. http:\/\/apps.who.int\/iris\/handle\/10665\/130997 ; http:\/\/apps.who.int\/iris\/handle\/10665\/137370 (2014). Accessed 14 Aug 2016."},{"key":"201_CR23","doi-asserted-by":"crossref","first-page":"g4997","DOI":"10.1136\/bmj.g4997","volume":"349","author":"S Arie","year":"2014","unstructured":"Arie S. Ebola: an opportunity for a clinical trial? BMJ. 2014;349:g4997.","journal-title":"BMJ"},{"key":"201_CR24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.345.6198.718","volume":"345","author":"M Enserink","year":"2014","unstructured":"Enserink M. Infectious diseases. Debate erupts on \u2018repurposed\u2019 drugs for Ebola. Science. 2014;345:718\u20139.","journal-title":"Science"},{"key":"201_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/phe\/phn037","volume":"2","author":"P Calain","year":"2009","unstructured":"Calain P, Fiore N, Poncin M, Hurst SA. Research ethics and international epidemic response: the case of Ebola and Marburg hemorrhagic fevers. Public Health Ethics. 2009;2:7\u201329.","journal-title":"Public Health Ethics"},{"key":"201_CR26","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(14)61734-7","volume":"384","author":"C Adebamowo","year":"2014","unstructured":"Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy JF, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384:1423\u20134.","journal-title":"Lancet"},{"key":"201_CR27","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.2014.12867","volume":"312","author":"S Joffe","year":"2014","unstructured":"Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014;312:1299\u2013300.","journal-title":"JAMA"},{"key":"201_CR28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.2014.17256","volume":"313","author":"MO Folayan","year":"2015","unstructured":"Folayan MO, Haire B, Peterson K. Ethical testing of experimental Ebola treatments. JAMA. 2015;313:421.","journal-title":"JAMA"},{"key":"201_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.2014.17259","volume":"313","author":"S Kanters","year":"2015","unstructured":"Kanters S, Thorlund K, Mills EJ. Ethical testing of experimental Ebola treatments. JAMA. 2015;313:421\u20132.","journal-title":"JAMA"},{"key":"201_CR30","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(14)61315-5","volume":"384","author":"A Rid","year":"2014","unstructured":"Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384:1896\u20139.","journal-title":"Lancet"},{"key":"201_CR31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMp1409858","volume":"371","author":"S Briand","year":"2014","unstructured":"Briand S, Bertherat E, Cox P, Formenty P, Kieny MP, Myhre JK, et al. The international Ebola emergency. N Engl J Med. 2014;371:1180\u20133.","journal-title":"N Engl J Med"},{"key":"201_CR32","unstructured":"Council for International Organizations of Medical Sciences (CIOMS): International Ethical Guidelines for Biomedical Research Involving Human Subjects. http:\/\/cioms.ch\/shop\/wp-content\/uploads\/2016\/08\/International_Ethical_Guidelines_for_Biomedical_Research_Involving_Human_Subjects.pdf (2002). Accessed 14 Aug 2016."},{"key":"201_CR33","unstructured":"WHO Ethics Working Group: Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease: WHO Ethics Working Group Meeting 20\u201321 October, Summary of Discussion. http:\/\/apps.who.int\/iris\/handle\/10665\/137509 (2014). Accessed 14 Aug 2016."},{"key":"201_CR34","first-page":"49","volume":"10","author":"D Schopper","year":"2017","unstructured":"Schopper D, Ravinetto R, Schwartz L, Kamaara E, Sheel S, Segelid MJ, et al. Research ethics governance in times of Ebola. Public Health Ethics. 2017;10:49\u201361.","journal-title":"Public Health Ethics"},{"key":"201_CR35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/lpr\/mgq006","volume":"9","author":"A Rid","year":"2010","unstructured":"Rid A, Wendler D. Risk-benefit assessment in medical research - critical review and open questions. Law Probability Risk. 2010;9:151\u201377.","journal-title":"Law Probability Risk"},{"key":"201_CR36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/medethics-2015-102882","volume":"42","author":"J Kimmelman","year":"2016","unstructured":"Kimmelman J, Henderson V. Assessing risk\/benefit for trials using preclinical evidence: a proposal. J Med Ethics. 2016;42:50\u20133.","journal-title":"J Med Ethics"},{"key":"201_CR37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(14)61735-9","volume":"384","author":"D Shaw","year":"2014","unstructured":"Shaw D. Randomisation is essential in Ebola drug trials. Lancet. 2014;384:1667.","journal-title":"Lancet"},{"key":"201_CR38","doi-asserted-by":"crossref","first-page":"g7518","DOI":"10.1136\/bmj.g7518","volume":"349","author":"SE Bellan","year":"2014","unstructured":"Bellan SE, Pulliam JR, Dushoff J, Meyers LA. Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net. BMJ. 2014;349:g7518.","journal-title":"BMJ"},{"key":"201_CR39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(15)70106-4","volume":"15","author":"S Lanini","year":"2015","unstructured":"Lanini S, Zumla A, Ioannidis JP, Di CA, Krishna S, Gostin L, et al. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lancet Infect Dis. 2015;15:738\u201345.","journal-title":"Lancet Infect Dis"},{"key":"201_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1740774515619877","volume":"13","author":"AH Beavogui","year":"2016","unstructured":"Beavogui AH, Delamou A, Yansane ML, Konde MK, Diallo AA, Aboulhab J, et al. Clinical research during the Ebola virus disease outbreak in Guinea: lessons learned and ways forward. Clin Trials. 2016;13:73\u20138.","journal-title":"Clin Trials"},{"key":"201_CR41","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","volume":"15","author":"A Huttner","year":"2015","unstructured":"Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial. Lancet Infect Dis. 2015;15:1156\u201366.","journal-title":"Lancet Infect Dis"},{"key":"201_CR42","unstructured":"Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe - preliminary report. N Engl J Med. 2015;"},{"key":"201_CR43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2105\/AJPH.2015.302996","volume":"106","author":"A Rid","year":"2016","unstructured":"Rid A, Miller FG. Ethical rationale for the Ebola \u201cring vaccination\u201d trial design. Am J Public Health. 2016;106:432\u20135.","journal-title":"Am J Public Health"},{"key":"201_CR44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505\u201318.","journal-title":"Lancet"},{"key":"201_CR45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","volume":"372","author":"EI Bah","year":"2015","unstructured":"Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40\u20137.","journal-title":"N Engl J Med"},{"key":"201_CR46","doi-asserted-by":"crossref","unstructured":"Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, et al. Ebola RNA persistence in semen of Ebola virus disease survivors - preliminary report. N Engl J Med. 2015;","DOI":"10.1056\/NEJMoa1511410"},{"key":"201_CR47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bmj.320.7227.79","volume":"320","author":"S Conroy","year":"2000","unstructured":"Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ. 2000;320:79\u201382.","journal-title":"BMJ"},{"key":"201_CR48","unstructured":"U.S: Food and Drug Administration: The Paediatric Exclusivity Provision: January 2001 Status Report to Congress. http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM049915.pdf . (2001). Accessed 12 Aug 2016."},{"key":"201_CR49","unstructured":"Woodcock, J.: Implementation of the Pediatric Exclusivity Provisions, Statement of Janet Woodcock, Director CDER, FDA, DHHS before Senate Committee on Health, Education, Labor and Pensions 2001. http:\/\/www.fda.gov\/NewsEvents\/Testimony\/ucm115220.htm (2001). Accessed 13 Aug 2016."},{"key":"201_CR50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5694\/j.1326-5377.2003.tb05498.x","volume":"179","author":"E Tan","year":"2003","unstructured":"Tan E, Cranswick NE, Rayner CR, Chapman CB. Dosing information for paediatric patients: are they really \u201ctherapeutic orphans\u201d? Med J Aust. 2003;179:195\u20138.","journal-title":"Med J Aust"},{"key":"201_CR51","first-page":"271","volume":"56","author":"Anonymous","year":"1978","unstructured":"Anonymous. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271\u201393.","journal-title":"Bull World Health Organ"},{"issue":"Suppl 1","key":"201_CR52","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/514289","volume":"179","author":"K Mupapa","year":"1999","unstructured":"Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De RA, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999;179(Suppl 1):S11\u20132.","journal-title":"J Infect Dis"},{"key":"201_CR53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1753495X15597354","volume":"8","author":"BO Black","year":"2015","unstructured":"Black BO, Caluwaerts S, Achar J. Ebola viral disease and pregnancy. Obstet Med. 2015;8:108\u201313.","journal-title":"Obstet Med"},{"key":"201_CR54","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/AOG.0000000000000853","volume":"125","author":"LM Bebell","year":"2015","unstructured":"Bebell LM, Riley LE. Ebola virus disease and Marburg disease in pregnancy: a review and management considerations for filovirus infection. Obstet Gynecol. 2015;125:1293\u20138.","journal-title":"Obstet Gynecol"},{"key":"201_CR55","unstructured":"World Health Organization: WHO First Consultation on Ebola Biobanking. http:\/\/www.who.int\/medicines\/ebola-treatment\/1st_consult_ebola_biobank\/en\/ ; (2015). Accessed 14 Aug 2016."},{"key":"201_CR56","unstructured":"World Health Organization: Report on the 2nd WHO COnsultation on Biobanking: Focus on West Africa. http:\/\/www.who.int\/medicines\/ebola-treatment\/meetings\/2nd_who_biobaking-consultation\/en\/ (2015). Accessed 14 Aug 2016."},{"key":"201_CR57","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2006.09.079","volume":"25","author":"CJ Acosta","year":"2007","unstructured":"Acosta CJ, Galindo CM, Ochiai RL, Danovaro-Holliday MC, Laure-Page A, Thiem VD, et al. Implementation of good clinical practice guidelines in vaccine trials in developing countries. Vaccine. 2007;25:2852\u20137.","journal-title":"Vaccine"},{"key":"201_CR58","unstructured":"ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use): Guideline for Good Clinical Practice, E6, R1, 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf (1996). Accessed 12 Apr 2017."},{"key":"201_CR59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMc1413685","volume":"372","author":"R Ansumana","year":"2015","unstructured":"Ansumana R, Jacobsen KH, Sahr F, Idris M, Bangura H, Boie-Jalloh M, et al. Ebola in Freetown area, Sierra Leone--a case study of 581 patients. N Engl J Med. 2015;372:587\u20138.","journal-title":"N Engl J Med"},{"key":"201_CR60","doi-asserted-by":"crossref","DOI":"10.17226\/24739","volume-title":"Integrating clinical research into epidemic Respons","author":"GT Keusch","year":"2017","unstructured":"Keusch GT, Adam K, Cuff P, Mancher M, Busta ER. Integrating clinical research into epidemic Respons. Washington, DC: The National Academies Press; 2017."},{"key":"201_CR61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QAI.0b013e318236eca3","volume":"58","author":"SK Shah","year":"2011","unstructured":"Shah SK, Dawson L, Dixon DO, Lie RK. Should sponsors and DSMBs share interim results across trials? J Acquir Immune Defic Syndr. 2011;58:433\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"201_CR62","first-page":"76","volume":"1","author":"M Crop De","year":"2016","unstructured":"De Crop M, Delamou A, Griensven JV, Ravinetto R. Multiple ethical review in north-south collaborative research: the experience of the Ebola-Tx trial in Guinea. Indian J Med Ethics. 2016;1:76\u201382.","journal-title":"Indian J Med Ethics"},{"key":"201_CR63","unstructured":"Nordic Trial Alliance Working Group on Ethics: Report on the Ethical Review Process for Clinical Trials in the Nordic Countries. The Challenges and Opportunities of the New Clinical Trials Regulation. http:\/\/nta.nordforsk.org\/news\/report-on-the-ethical-review-process-for-clinical-trials-in-the-nordic-countries (2016). Accessed 12 Apr 2017."},{"key":"201_CR64","unstructured":"Alexander, D.: Global Health Issues and US Regulation 45CFR46, Subpart B. In: Enrolling pregnant women. Issues in Clinical Research. US Department of Health and Human Services. https:\/\/orwh.od.nih.gov\/resources\/pdf\/ORWH-EPW-Report-2010.pdf (2011). Accessed 14 Aug 2016."},{"key":"201_CR65","volume-title":"Enrolling pregnant women: issues in clinical research","author":"U.S.Department of Health and Human Services","year":"2011","unstructured":"U.S.Department of Health and Human Services. Enrolling pregnant women: issues in clinical research. Bethesda: National Institutes of Health; 2011."},{"key":"201_CR66","unstructured":"Lyerly, A. D.: Direct Benefit to Pregnant Women. In: Enrolling pregnant women. Issues in Clinical Research. US Department of Health and Human Services. https:\/\/orwh.od.nih.gov\/resources\/pdf\/ORWH-EPW-Report-2010.pdf (2011). Accessed 14 Aug 2016."},{"key":"201_CR67","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/AOG.0b013e3182a9ca67","volume":"122","author":"KE Shields","year":"2013","unstructured":"Shields KE, Lyerly AD. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol. 2013;122:1077\u201381.","journal-title":"Obstet Gynecol"},{"key":"201_CR68","unstructured":"Little, M. O.: Treating Important Medical Conditions during Pregnancy. In: Enrolling pregnant women. Issues in Clinical Research. US Department of Health and Human Services. https:\/\/orwh.od.nih.gov\/resources\/pdf\/ORWH-EPW-Report-2010.pdf (2011). Accessed 14 Aug 2016."},{"key":"201_CR69","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.61.5.673","volume":"61","author":"LB Holmes","year":"2004","unstructured":"Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol. 2004;61:673\u20138.","journal-title":"Arch Neurol"},{"key":"201_CR70","unstructured":"Addy, R. The state of pediatric research in the United States: Successes under BCPA & PREA. Presentation at DIA 2015. www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/developmentresources\/ucm452231.pdf (2015). Accessed 14 Aug 2016."}],"updated-by":[{"DOI":"10.1186\/s12910-017-0204-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000}}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-017-0201-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T22:35:35Z","timestamp":1569537335000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedethics.biomedcentral.com\/articles\/10.1186\/s12910-017-0201-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1186\/s12910-017-0201-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727757712.793541703","asserted-by":"object"}]},"ISSN":["1472-6939"],"issn-type":[{"value":"1472-6939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]},"article-number":"43"}}